Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Traws Pharma (TRAW) over the last 14 years, with Q1 2025 value amounting to $2.5 million.

  • Traws Pharma's Non-Current Deffered Revenue fell 829.98% to $2.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.5 million, marking a year-over-year decrease of 829.98%. This contributed to the annual value of $2.6 million for FY2024, which is 809.75% down from last year.
  • Traws Pharma's Non-Current Deffered Revenue amounted to $2.5 million in Q1 2025, which was down 829.98% from $2.6 million recorded in Q4 2024.
  • Over the past 5 years, Traws Pharma's Non-Current Deffered Revenue peaked at $3.4 million during Q1 2021, and registered a low of $2.5 million during Q1 2025.
  • Moreover, its 5-year median value for Non-Current Deffered Revenue was $3.0 million (2023), whereas its average is $3.0 million.
  • As far as peak fluctuations go, Traws Pharma's Non-Current Deffered Revenue tumbled by 621.05% in 2021, and later tumbled by 829.98% in 2025.
  • Over the past 5 years, Traws Pharma's Non-Current Deffered Revenue (Quarter) stood at $3.2 million in 2021, then decreased by 6.97% to $3.0 million in 2022, then dropped by 7.49% to $2.8 million in 2023, then fell by 8.1% to $2.6 million in 2024, then dropped by 2.22% to $2.5 million in 2025.
  • Its Non-Current Deffered Revenue stands at $2.5 million for Q1 2025, versus $2.6 million for Q4 2024 and $2.6 million for Q3 2024.